This is supported by our findings that female UK Biobank SLCO1B1*5 homozygotes who self‐reported statin therapy at baseline were significantly more likely to report headaches than normal function homozygotes (12.7% of *5 group reported chronic headache for 3+ months compared to 9.6% of normal group). Here, SLCO1B1 is linked to headache disorder.